(INNS)
BRENETAFUSP(INNC)
HUMANIZED IMMUNOGLOBULIN ANTI-(HUMAN T-CELL SURFACE GLYCOPROTEIN CD3 EPSILON CHAIN) SINGLE CHAIN VARIABLE FRAGMENT (SCFV) (1-253) CONTAINING THE LIGHT CHAIN VARIABLE (VL) REGION (1-107), THE LINKER ^108GGGGSGGGGSGGGGSGGGGSGGGS^131 AND THE HEAVY CHAIN VARIABLE (VH) REGION (132-253) FUSED VIA THE PEPTIDE LINKER ^254GGGGS^258 TO A HUMAN T-CELL RECEPTOR BETA CHAIN ANTI-(HUMAN HLAA2 ANTIGEN COMPLEX WITH PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME) PROTEIN) FRAGMENT (259-502 IN THE CURRENT SEQUENCE) ENGINEERED VARIANT (S^429>C, C^447>A, N^461>D), DISULFIDE BRIDGED TO A HUMAN T CELL RECEPTOR ALPHA CHAIN ANTI-(HUMAN HLA-A2 ANTIGEN COMPLEX WITH PREFERENTIALLY EXPRESSED ANTIGEN IN MELANOMA (PRAME) PROTEIN) FRAGMENT (1-201), ENGINEERED VARIANT (T^163>C), NONGLYCOSYLATED, PRODUCED IN ESCHERICHIA COLI;...PROPOSED INN: LIST 128, RECOMMENDED INN: LIST 90(WHO)
BRENETAFUSPUM(INN)